Optometry Podcast: Pataday® Family of Products: Prescription Strength Relief, Available OTC

This podcast is sponsored by Alcon. Defocus Media and Dr. Eric Donnenfeld were compensated by Alcon for their participation.  

For many patients, ocular allergy itch is a real problem. About 66 million Americans suffer with ocular allergies each year1 and this time of the year, Spring, is when allergies are bad for many people.2 Itchy eyes is the most common symptom of eye allergies3,4 and can negatively impact quality of life.5-8 

The Pataday Family of OTC products were designed to address ocular allergy symptoms at the source and feature the same dual-action prescription formulations we have been prescribing for years to provide the relief our patients need. On this episode, Drs. Lyerly and Glover are joined by Dr. Eric Donnenfeld from  Garden City, NY, to discuss how the Pataday Family of OTC products–and a strong ECP recommendation– can allow our patients to continue to get the ocular allergy symptom relief they need. 

1. Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol. 2014;14:451-456. 

2. American College of Allergy, Asthma & Immunology. Seasonal Allergies. Updated December 28, 2017. https://acaai.org/allergies/seasonal-allergies. Accessed February 24, 2021. 

3. Alcon data on file, 2011. 

4. Ono SJ and Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118-122. 

5. Bielory L, Skoner DP, Blaiss MS, et al. Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) Survey. Allergy Asthma Proc. 2014;35:211- 218. 

6. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:471-476. 

7. Virchow JC, Kay S, Demoly P, et al. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilization in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ. 2011;14:305-314. 

8. Charter L. Examining ocular allergy, quality of life. Ophthalmology Times. November 2020. Available at: https://www.ophthalmologytimes.com/view/examining-ocular-allergy-quality-of-life. Accessed February 23, 2021.

© 2021 Alcon Inc. US-PTD-2100127 

Reference list for Podcast 

1. Mangan RB. When allergy and dry eye collide. Rev Optom. August 17, 2009. https://www.reviewofoptometry.com/article/when-allergy-and-dry-eye-collide. Accessed May 24, 2021.

2. Bielory L, Skoner DP, Blaiss MS, et al. Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and Rhinoconjunctivitis (AIRS) Survey. Allergy Asthma Proc. 2014;35:211-218.

3. Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:471-476.

4. Jackson JM. Allergies and contact lenses. Contact Lens Spectrum. April 2002. Available at: https://www.clspectrum.com/issues/2002/april-2002/allergies-and-contact-lenses. Accessed February 23, 2021.

5. Virchow JC, Kay S, Demoly P, et al. Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilization in allergic rhinitis patients – an observational, cross sectional study in four countries in Europe. J Med Econ. 2011;14:305-314.

6. Charter L. Examining ocular allergy, quality of life. Ophthalmology Times. November 2020. Available at: https://www.ophthalmologytimes.com/view/examining-ocular-allergy-quality-of-life. Accessed February 23, 2021.

7. Ono SJ and Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118-122.

8. Alcon data on file, 2011.

9. Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol. 2014;14:451-456

10. US Census Bureau. Table 9

11. American College of Allergy, Asthma & Immunology. Seasonal Allergies. Updated December 28, 2017. https://acaai.org/allergies/seasonal-allergies. Accessed February 24, 2021.

12. Ayaki M et al. Sleep and mood disorders in dry eye disease and allied irritating ocular disease. Sci Rep. 2016;6:22480

13. Hauswirth S. The Interaction of Dry Eye and Ocular Allergy. Cataract & Refractive Surgery Today. 2017:58-60

14.  Dupuis P et al. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5.

15.  Alcon data on file, 2019.

16. Pataday Once Daily Relief Extra Strength (0.7%) product information. Alcon Laboratories, Inc. Fort Worth, Texas. 2020

17. Pataday Once Daily Relief (olopatadine hydrochloride solution) product information. Alcon Laboratories, Inc. Fort Worth, Texas. 2020.

18. Pataday Twice Daily Relief (olopatadine hydrochloride solution) product information. Alcon Laboratories, Inc. Fort Worth, Texas. 2020.

19. Aydin E, Gokhale M, Azizoglu S, Suphioglu C. To see or not to see: a systematic review of the importance of human ocular surface cytokine biosignatures in ocular allergy. Cells. 2019;8:620.

20. Chaglasian EL. Relieve patients’ itchy, irritated eyes. Rev Optom. 2011. Available at https://www.reviewofoptometry.com/article/relieve-patients-itchy-irritated-eyes. Accessed February 25, 2021.

21. Sorrenson, L. Making an Impact on Allergies. Optometric Management. 2008. Available at: https://www.optometricmanagement.com/issues/2008/may-2008/making-an-impact-on-allergies. Accessed January 30, 2020.

22. Abelson MB. A Review of Olopatadine for the Treatment of Ocular Allergy. Expert Opin Pharmacother. 2004;5:1979-1194.

23. Lichtenstein SJ, Abelson MB. Pharmacology, clinical efficacy and safety of olopatadine hydrochloride. Expert Rev Clin Immunol. 2006;2:341-351. 

24. McLaurin E et al. Phase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis using the Conjunctival Allergen Challenge Model. Cornea. 2015;34:1245-1251.

25. Abelson MB et al. Efficacy of olopatadine hydrochloride ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc. 2007;28:427-433.

26. Abelson MB, Welch DL. An evaluation of onset and duration of action of Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl. 2000;60-63.

27. Alcon data on file, 2006.

28. Meier E et al. Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies. Clin Ophthalmol. 2017;11:669-681

© 2021 Alcon Inc. US-PTD-2100078

Drs. Glover & Lyerlyhttps://www.defocusmedia.com
Defocus Media is run by two successful Millennial optometrists and social media entrepreneurs, Dr. Jennifer Lyerly and Dr. Darryl Glover. They have proven track records of successfully engaging online readers and followers. They reside and practice in North Carolina.

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Latest Posts